Using Boceprevir (Victrelis ®) for patients who are co-infected with "HCV genotype 1 and HIV-1"

Study Objective

Control of viral replication (multiplication) for HCV genotype 1 for patients co-infected with HIV-1.
Monitor possible side effects of Boceprevir in combination with standard therapy.

Participation conditions

Inclusion criteria

• Being co-infected with HIV-1 and HCV genotype 1
• Being stable (viral replication should be controlled: undetectable viral load) for HIV
• Being at least at the second stage of fibrosis (F2) in the context of HCV genotype 1 infection.
• Being an adult (18 years old at least)

Exclusion criteria

• Being  an active addict
• Having one of the following three molecules in the regime against HIV-1: stavudine, zidovudine and didanosine.
• Being pregnant
• Feeding

Centre Hospitalier de Luxembourg